AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04868747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: The participants receive perioperative lidocaine infusion with general anesthesia for gastrectomy.
Study NCT04868747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: The participants receive perioperative normal slaine infusion with general anesthesia for gastrectomy.
Study NCT05731232 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vivatlac Synbiotikum
Description: Each capsule of Vivatlac® Synbiotikum contains a total of 4.5 x 10˄9 colony forming units (CFU) of nine different probiotic bacteria. Probiotic bacteria strains and their CFU amount per capsule are: Lactococcus lactis Ll-23, 9.00 x 10˄8 CFU; Lactobacillus helveticus SP 27, 9.00 x 10˄8 CFU; Bifidobacterium longum Bl-05, 6.75 x 10˄8 CFU; Bifidobacterium breve Bb-03, 4.50 x 10˄8 CFU; Lacticaseibacillus rhamnosus Lr-32, 4.50 x 10˄8 CFU; Streptococcus thermophiles St-21, 4.50 x 10˄8 CFU; Lacticaseibacillus casei Lc-11, 2.25 x 10˄8 CFU; Lactiplantibacillus plantarum Lp-115, 2.25 x 10˄8 CFU; Bifidobacterium bifidum Bb-02, 2.25 x 10˄8 CFU. As a prebiotic component each capsule contains 63 mg of fructooligosaccharides.
Study NCT05731232 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vivatlac Synbiotikum
Description: Each capsule of Vivatlac® Synbiotikum contains a total of 4.5 x 10˄9 colony forming units (CFU) of nine different probiotic bacteria. Probiotic bacteria strains and their CFU amount per capsule are: Lactococcus lactis Ll-23, 9.00 x 10˄8 CFU; Lactobacillus helveticus SP 27, 9.00 x 10˄8 CFU; Bifidobacterium longum Bl-05, 6.75 x 10˄8 CFU; Bifidobacterium breve Bb-03, 4.50 x 10˄8 CFU; Lacticaseibacillus rhamnosus Lr-32, 4.50 x 10˄8 CFU; Streptococcus thermophiles St-21, 4.50 x 10˄8 CFU; Lacticaseibacillus casei Lc-11, 2.25 x 10˄8 CFU; Lactiplantibacillus plantarum Lp-115, 2.25 x 10˄8 CFU; Bifidobacterium bifidum Bb-02, 2.25 x 10˄8 CFU. As a prebiotic component each capsule contains 63 mg of fructooligosaccharides.
Study NCT05847647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retrograde Filling Group
Description: Surgical curettage of the periapical lesion and root tip resection will be performed, MTA will be applied retrogradely and no material will be applied to the bone defect.
Study NCT05847647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retrograde Filling+L-PRF Group
Description: 2. Group: Surgical curettage of the periapical lesion and root tip resection will be performed, MTA will be applied retrogradely and L-PRF will be applied to the bone defect (
Study NCT05847647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: (Orthograde Filling Group / OG Group).
Description: 3. Group: Surgical curettage of the periapical lesion will be performed, MTA will be applied orthogradely without root tip resection and no material will be applied to the bone defect
Study NCT06288022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: total tubeless mini-PCNL
Description: When finish the mini-PCNL operation, patient not receive placement both ureteral drainage tube (DJ-stent) and nephrostomy tube.
Study NCT06288022 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tubeless mini-PCNL
Description: When finish the mini-PCNL operation, patient receive placement ureteral drainage tube (DJ-stent) but not receive nephrostomy tube.
Study NCT05884242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab will be administered subcutaneously.
Study NCT05884242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide (LPS)
Description: LPS will be administered intravenously.
Study NCT05160493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine and pregabalin
Description: S-ketamine and pregabalin~* Drug: Pregabalin • 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7),followed by dose reduction to 75mg once daily for 7days(POD8-14)~* Drug: S-ketamine infusion • 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h
Study NCT05160493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline and placebo capsule
Description: Normal saline and placebo capsule
Study NCT05548816 — intervention group
Intervention type: OTHER
Intervention: Handheld Dynamometer , Special tests and Modified DASH questionarre .
Description: A mix of tools , special tests and questionarre to help in confirming the diagnosis of subacromial impingement.
Study NCT05379855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% atropine eye drops
Description: using 0.01% atropine eye drops for both eyes every night
Study NCT05032638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist guided training
Description: Therapist guided period delivered virtually (WebEx/Zoom). Participants will be patients associated with NYULH and will have access to Zoom. Each session will last 45 min, and will completed 3x/week by research therapists, who are part of the study.
Study NCT06145152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adaptive exercise training
Description: The training recommendation for the day will be adjusted based on the readiness level. The adjustments can be both up or down (increased or decreased training)
Study NCT06145152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Static exercise training
Description: The training recommendation for the day will not be adjusted based on the readiness level.
Study NCT05716815 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CT scans 2D Reconstruction
Description: Before performing the surgery, patient performs a chest CT scan with contrast medium and standard two-dimensional (2D) reconstructions are performed to study the lesion, the anatomy of the bronchi and the pulmonary venous and arterial vessels.
Study NCT05716815 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT scans 2D plus 3D Reconstruction
Description: Before performing the surgery, patient performs a chest CT scan with contrast medium and standard two-dimensional (2D) reconstructions plus a 3D reconstruction are performed to study the lesion, the anatomy of the bronchi and the pulmonary venous and arterial vessels.
Study NCT05475574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation of contact precautions for ESBLE
Description: Discontinuation of contact precaution : only standard precaution are implemented for any patient carrying (infected or colonized) ESBLE
Study NCT05647018 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Percutaneous coronary angiography
Description: Percutaneous coronary intervention (PCI) refers to a family of minimally invasive procedures used to open clogged coronary arteries in patients presenting with myocardial infarction, through which installment of stents or intracoronary injection of drugs can take place.
Study NCT05010525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-016
Description: 48 patients enrolled, orally, each 3 week (21-day) a cycle
Study NCT06410924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DD01
Description: Dual GLP-1 and glucagon receptor agonist
Study NCT06410924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching DD01
Study NCT05379855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo eye drops (0.1% sodium hyaluronate ophthalmic solution)
Description: using placebo eye drops (0.1% sodium hyaluronate ophthalmic solution) for both eyes every night
Study NCT05379855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.05% atropine eye drops
Description: using 0.05% atropine eye drops for both eyes every night
Study NCT05218382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: immersive virtual reality technology
Study NCT05218382 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: No virtual reality
Description: Virtual reality with blank screen
Study NCT05847647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: (Orthograde Filling+L-PRF Group
Description: 4. Group: Surgical curettage of the periapical lesion will be performed, MTA will be applied orthogradely without root tip resection and L-PRF will be applied to the bone defect
Study NCT05073939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Oxytocin
Description: Administration of oxytocin (24 international units) orally
Study NCT05073939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Administration of placebo orally
Study NCT05200052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.5 mg Oral Tablet
Description: Colchicine loading dose 1 mg and maintenance dose 0.5 mg for 6 months in addition to standard anti ischemic treatment.
Study NCT05092880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radioembolization
Description: holmium-166 microspheres
Study NCT05092880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care first-line systemic therapy
Description: Capecitabine plus anti-VEGF antibody
Study NCT04857463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional supplement drink
Description: At the intervention period (0th to 12th week of the experiment), In addition to nutrition and health education, subjects were provided with 2 bottles of commercially available oral nutritional supplements (Meiji Mei Balance, Meiji Co., Ltd., Tokyo, Japan) every day, between lunch and dinner and before bedtime.
Study NCT04857463 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional education
Description: At the intervention period (0th to 12th week of the experiment) , subjects will be given regular nutrition education by a qualified clinical dietitian to ensure the effectiveness of nutrition education, in order for the nutrition education group to benefit from participating in this trial, the subjects will also be provided with the same nutritional products after the trial
Study NCT06469489 — intervention group
Intervention type: OTHER
Intervention: Liver Disease of all etiologies
Description: No intervention
Study NCT04979273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 40 % in Water
Description: injection of adrenaline 1:20.000, followed by dextrose 40% spray
Study NCT04979273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenaline 1 Mg/mL Solution for Injection
Description: injection of adrenaline 1:20.000, followed by thermocoagulation or hemoclip
Study NCT04979273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenaline 1 Mg/mL Solution for Injection
Description: injection of adrenaline 1:20.000, followed by thermocoagulation or hemoclip
Study NCT04979273 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: argon plasma coagulation
Description: Thermocoagulation
Study NCT04979273 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemoclip
Description: Hemoclip
Study NCT05389982 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mHealth (GetWell)
Description: GetWell Loop utilizes an interactive health care application to allow patients to more actively participate in their care. We plan to work with GetWell to develop a custom build plan for kidney stone formers to achieve key aspects of stone prevention and provide patient education. This care plan will be developed using native capabilities within GetWell Loop.
Study NCT05389982 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: Office based pathway
Study NCT05389982 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Office based pathway
Study NCT05006872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIABE-TEXT
Description: Participants will receive 170 text messages in their mobile phones during twelve months.
Study NCT04962984 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: blood sampling
Description: additional blood sampling for coagulation tests
Study NCT04962984 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: additional blood sampling for coagulation tests
Study NCT05534308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoperative taping
Description: The intervention group (IG) will be composed of patients undergoing phleboextraction with saphenectomy and intervention with contensive taping, on intraoperative period associated with compression with elastic stockings.
Study NCT05534308 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No trasoperative taping
Description: Patients will received only compression stockings after surgery
Study NCT06236932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: Hypocaloric Mediterranean Diet consist of a nutritional regimen with customized daily energy intake, calculated considering the Basal Metabolism and Physical Activity Level (LAF) of each patient. The distribution of macronutrients will be worked out as follows: ≃ 55-60% Carbohydrates (of which 80% are complex carbohydrates, pasta, bread, rice, whole grains and 20% simple sugars), ≃ 10-15% Proteins (of which the 60% of animal origin (meat, especially white) and 40% of vegetable origin (beans, chickpeas, lentils and legumes in general), ≃ 25-30% of lipids (predominantly olive oil).
Study NCT06236932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin supplementation
Description: Melatonin (supplement formulation in capsules, 1mg/die one hour before sleep) will be associated with mediterranean diet for 12 w.
Study NCT06271720 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: visceral manipulation
Description: visceral manipulation: A palpation technique will be applied till the barrier is felt and it will be applied until release is felt.~integrated neuromuscular inhibition: ischemic compression will be applied to trigger point of upper trapezius
Study NCT06271720 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: integrated neuromuscular inhibition
Description: It involves applying direct sustained digital pressure to the TrP with sufficient force over dedicated time duration, to slow down the blood supply and relieve the tension within the involved muscle. The pressure is gradually applied, maintained and the gradually released
Study NCT05931666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gong Mobilization
Description: Patients are treated with Gong mobilization protocol along with conventional therapy including ultrasound therapy, hot pack and conventional exercises consisting of codman exercises, ROM exercises and shoulder stabilization exercises.~Total of 3 sessions per week for 3 consecutive weeks.
Study NCT05931666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kaltenborn Mobilization
Description: Patients are treated with Kaltenborn mobilization protocol along with conventional therapy including ultrasound therapy, hot pack and conventional exercises consisting of codman exercises, ROM exercises and shoulder stabilization exercises.~Total of 3 sessions per week for 3 consecutive weeks.
Study NCT05834166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper back strengthening and Postural correction
Description: The treatment protocol will involve upper back strengthening exercises and postural correction exercises 3 times a week for 10 to 15 minutes. Upper back strengthening will involve exercises with light-to-moderate load of free weights (body weight or resistance bands) or with a stability ball. Postural correction will involve maintaining the correct posture.
Study NCT06082869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protegera™ toothpaste (NaF)
Description: Plaque Reduction
Study NCT06082869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crest™ Cavity Protection toothpaste (NaF)
Description: Plaque Reduction
Study NCT05181904 — intervention group
Intervention type: OTHER
Intervention: Gastric ultrasound
Description: Assessment of gastric content with gastric ultrasound monitoring: gastric ultrasounds will be performed in eligible children, when enteral feeding is stopped for planned extubation, and repeated 6 hours after, at extubation and every hour between feeding interruption and extubation. The stomach will be classified as empty or full according to PERLAS criteria. In total, 8 gastric ultrasounds will be performed over a period of 12 hours.
Study NCT05781763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT)
Description: 2 HIIT sessions/week in self-selected activity and type of interval-session with in total 15 minutes interval time (85-90% of MHR) with active rest (50-70% of MHR) between intervals for 12 weeks~1 self-selected session at moderate or high-intensity/week for 12 weeks Standardized physical and digital coaching by a physiotherapist
Study NCT05781763 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Continuing with exercise as usual during 12 months
Study NCT04904965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol Group 1
Description: Propofol 2.0 mg/kg/hr per 10 min
Study NCT04904965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol Group 2
Description: Propofol 4.0 mg/kg/hr per 10 min
Study NCT04904965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol Group 3
Description: Propofol 6.0 mg/kg/hr per 10 min
Study NCT04904965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol Group 4
Description: Propofol 8.0 mg/kg/hr per 10 min
Study NCT00819975 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Casein
Study NCT05486936 — intervention group
Intervention type: RADIATION
Intervention: hypofractionated radiation
Description: Eligible breast cancer patients will receive hypofractionated radiotherapy of 2.67 Gy for 16 fractions (and sequential tumor bed boost of 2.67 Gy for 4 fractions in patients with intact breast) to ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) at the discrection of radition oncologists.
Study NCT04878393 — intervention group
Intervention type: DRUG
Intervention: Oral semaglutide
Description: Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Study NCT06513533 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet twice daily (one in the morning and one in the evening) for the first 7 days as a starter dose followed by 2 tablets (240 mg) twice daily
Study NCT06513533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate
Description: 1 tablet twice daily (one in the morning and one in the evening) for the first 7 days as a starter dose followed by 2 tablets (240 mg) twice daily
Study NCT06361004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Description: The DBS lead is stereotactically introduced into the target in the brain (GPi, amGPi, pvGPi, Cm-Spv-Voi, Cm-Voi, NA-ALIC, or other unreported nuclei targets) and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.
Study NCT00819975 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Isolate
Study NCT00819975 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Hydrolysate
Study NCT00819975 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alphalact-Albumin
Study NCT05137470 — intervention group
Intervention type: OTHER
Intervention: This is an observational study
Description: This is an observational study
Study NCT05079763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bacterial cellulose-monolaurin hydrogel
Description: Hydrogel containing Komagataeibacter bylines-derived bacterial cellulose, virgin coconut oil monolaurin, cucumber fragrance and distilled water
Study NCT05079763 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Cream containing distilled water, white petrolatum, steady alcohol, propylene glycol, sodium laurel sulphate, methylparaben and propylparaben
Study NCT05541484 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SGLT2 inhibitor
Description: See above.
Study NCT05541484 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Biosense Breath Ketone Analyzer
Description: The hand-held device tests ketones in exhaled breath
Study NCT04781348 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma plus fat grafting
Description: The study participants fulfilling the inclusion criteria giving consent will be randomly divided into two groups, one group will receive only fat grafting whereas another group will receive Platelet Rich Plasma plus fat grafting.
Study NCT06482775 — intervention group
Intervention type: DRUG
Intervention: dexmedetomidine
Description: The dosing and administration will be implemented according to an algorithm based on pain scoring results
Study NCT06364956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with two predefined dose groups of palbociclib
Description: Tislelizumab, 200mg q3W, combined with two predefined dose groups of palbociclib: 100mg QD and 125mg QD, separately.